Related Experiment Video

Updated: Jun 14, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry)

Peter R Kowey1, James A Reiffel, Robert Myerburg

  • 1Jefferson Medical College, Philadelphia, Pennsylvania, USA. koweypr@mlhs.org

The American Journal of Cardiology
|April 13, 2010
PubMed

Insights

Warfarin use for atrial fibrillation (AF) stroke prevention is suboptimal. High-risk AF patients were often undertreated, while low-risk patients were overtreated, indicating a need for better physician education on anticoagulation guidelines.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Atrial fibrillation (AF) poses a significant risk of thromboembolism.
  • Warfarin use for stroke prevention in high-risk AF patients remains low despite guidelines.

Purpose of the Study:

  • To assess anticoagulation patterns in AF patients using data from the AFFECTS Registry.
  • To evaluate warfarin utilization based on physician-assessed stroke risk and CHADS(2) scores.

Main Methods:

  • Analysis of anticoagulation use (warfarin, aspirin) in AF patients from the AFFECTS Registry.
  • Post hoc analysis of warfarin use stratified by CHADS(2) score and treatment strategy (rate vs. rhythm control).

Main Results:

  • 74% of high-risk AF patients received warfarin, and 29% received aspirin.
  • Warfarin use was higher in patients with CHADS(2) score >= 2 compared to < 2, but still below guideline recommendations.
  • A considerable proportion of high-risk patients did not receive warfarin, while some low-risk patients were overprescribed anticoagulants.

Conclusions:

  • Physician education on appropriate anticoagulation for AF is crucial.
  • Current warfarin prescribing practices do not fully align with evidence-based guidelines.
  • Optimizing anticoagulation in AF requires addressing both undertreatment in high-risk and overtreatment in low-risk populations.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...